These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Skin ulcer at the injection site of BNT162b2 mRNA COVID-19 vaccine. Aoki N; Saruta Y; Tanaka S; Nakajima R; Sano H; Sano S J Dermatol; 2021 Dec; 48(12):e596-e597. PubMed ID: 34545609 [No Abstract] [Full Text] [Related]
6. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months. Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627 [No Abstract] [Full Text] [Related]
7. Re: Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Mungmunpuntipantip R; Wiwanitkit V Ultrasound Obstet Gynecol; 2021 Dec; 58(6):958. PubMed ID: 34855292 [No Abstract] [Full Text] [Related]
8. Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents. Van Praet JT; Vandecasteele S; De Roo A; De Vriese AS; Reynders M Clin Infect Dis; 2021 Dec; 73(11):2145-2147. PubMed ID: 33825869 [No Abstract] [Full Text] [Related]
13. Nonepisodic Angioedema with Eosinophilia Following Receipt of the BNT162b2 mRNA COVID-19 Vaccine. Koda T; Natsumoto B; Shoda H; Fujio K Intern Med; 2023 Oct; 62(20):3063-3067. PubMed ID: 37468248 [TBL] [Abstract][Full Text] [Related]
14. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513 [No Abstract] [Full Text] [Related]
15. Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Mungmunpuntipantip R; Wiwanitkit V Rheumatology (Oxford); 2021 Dec; 61(1):e29. PubMed ID: 34554230 [No Abstract] [Full Text] [Related]
16. A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer). Fukushima T; Tomita M; Ikeda S; Hattori N QJM; 2022 Jan; 115(1):25-27. PubMed ID: 34871447 [No Abstract] [Full Text] [Related]
17. Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series: reply. Furer V; Zisman D; Elkayam O Rheumatology (Oxford); 2021 Dec; 61(1):e30. PubMed ID: 34554242 [No Abstract] [Full Text] [Related]
18. Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021. Lassaunière R; Polacek C; Fonager J; Bennedbæk M; Boding L; Rasmussen M; Fomsgaard A Euro Surveill; 2021 Dec; 26(49):. PubMed ID: 34886943 [TBL] [Abstract][Full Text] [Related]
20. Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle? Mazzatenta C; Piccolo V; Pace G; Romano I; Argenziano G; Bassi A J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):e543-e545. PubMed ID: 34048614 [No Abstract] [Full Text] [Related] [Next] [New Search]